Hims & Hers Health, Inc. (HIMS)
NYSE • Healthcare
September 10, 2026 at 16:24 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Hims & Hers Health, Inc. currently loses $11.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 60 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Hims & Hers Health beat revenue consensus in the second fiscal quarter of 2026, based on preliminary results reported Aug. 10, as revenue rose about 38% to roughly $753.2 million from about $544.8 million a year ago and came in about 8% above the $698.9 million estimate. Gross profit reached about $577.3 million, with gross margin near 77%, while operating cash flow was negative $35.9 million. Consensus for the next period calls for EPS of $0.12 on revenue of $792.2 million.
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (NYSE: HIMS) provides consumer-focused healthcare products and services across prescription and nonprescription categories, operating in healthcare with an emphasis on medical products, related services, and digital access. The company generated $2.3 billion in FY2025 revenue.
Today's Snapshot
HIMS opened 2.1% lower at 27.30, in line with a flat sector. Hims & Hers faces a shareholder class action announced by Portnoy Law Firm, a plaintiffs’ law firm.
Trading Volume
Below 10d avg (8.7M)
3.2M
vs S&P 500 Today
Moderate Outperformance
+0.18%
Updated: September 10, 2026 at 15:08 UTC
HIMS Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$28.57 - $32.24Sell
- RSI (14)43.76Neutral
- Stochastic %K (14, 3, 3)9.64Buy
- MACD Level (12, 26)-0.78Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.